- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 26.10. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - RESEARCH RESULTS OF SATRI-CEL AT THE ESMO CONGRESS 2026 | 2 | HKEx | ||
| 13.10. | CARSGEN-B Completes First Patient Infusion in China Phase I Trial of CT0596 | 1 | AASTOCKS | ||
| 13.10. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSE OF CT0596 IN CHINA PHASE I REGISTRATIONAL TRIAL | 1 | HKEx | ||
| 30.09. | CARSGEN-B (02171): LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS | 1 | HKEx | ||
| 30.09. | CARSGEN-B (02171): RESIGNATION OF NON-EXECUTIVE DIRECTOR AND NON-COMPLIANCE WITH RULE 3.21 OF THE LISTING RULES | - | HKEx | ||
| 29.09. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - FIRST PATIENT DOSE OF CT1190B IN CHINA PHASE I REGISTRATIONAL TRIAL | 3 | HKEx | ||
| 15.09. | CARSGEN-B (02171): INTERIM REPORT 2026 | - | HKEx | ||
| 19.08. | CARsgen Therapeutics Announces 2026 Interim Results | 313 | PR Newswire | SHANGHAI, Aug. 18, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its... ► Artikel lesen | |
| CARSGEN THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 18.08. | CARSGEN-B (02171): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 1 | HKEx | ||
| 07.08. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - CT1190B RECEIVED IND CLEARANCE FROM THE NMPA FOR PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R ... | 1 | HKEx | ||
| 06.08. | CARSGEN-B (02171): DATE OF BOARD MEETING | 2 | HKEx | ||
| 04.08. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - CT0596 RECEIVED IND CLEARANCE FROM THE NMPA FOR THE TREATMENT OF PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE ... | 3 | HKEx | ||
| 17.07. | CARSGEN-B (02171): NEXT DAY DISCLOSURE RETURN | - | HKEx | ||
| 15.07. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - ABSTRACT OF RESEARCH RESULTS ON SATRI-CEL ACCEPTED FOR POSTER PRESENTATION AT ESMO CONGRESS 2026 | 1 | HKEx | ||
| 07.07. | CARSGEN-B (02171): NEXT DAY DISCLOSURE RETURN | 1 | HKEx | ||
| 26.06. | CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - SHARE REPURCHASE BY THE COMPANY | 1 | HKEx | ||
| 24.06. | China's CARsgen Slides for Second Day on Hefty Price Tag for World's First Solid Tumor CAR-T Therapy | 3 | Yicai Global | ||
| 22.06. | CARsgen makes history as China approves world's first CAR-T therapy for solid tumors | 1 | FiercePharma | ||
| 22.06. | CARSgen bags world-first approval for solid tumour CAR-T | 2 | pharmaphorum | ||
| 22.06. | CARsgen's Solid-Tumor CAR-T Therapy Nears China Approval, a Global First | 1 | Yicai Global |
1 2 Weiter >>
32 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| QIAGEN | 45,020 | 0,00 % | BARCLAYS stuft QIAGEN NV auf 'Equal Weight' | LONDON (dpa-AFX Analyser) - Die britische Investmentbank Barclays hat das Kursziel für Qiagen von 55 auf 53 US-Dollar gesenkt und die Aktien von "Overweight" auf "Equal Weight" abgestuft. Analyst Luke... ► Artikel lesen | |
| RELAY THERAPEUTICS | 17,440 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026 | ||
| SUMMIT THERAPEUTICS | 15,800 | 0,00 % | Summit Therapeutics (NDQ:SMMT): The Company Bringing the First Bispecific Immunotherapy into Mainstream Lung Cancer | ||
| KYMERA THERAPEUTICS | 127,09 | 0,00 % | Oppenheimer raises Kymera Therapeutics price target on drug data | ||
| IMMUNOVANT | 29,040 | 0,00 % | Immunovant Inc.: Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026 | IMVT-1402 showed clinically meaningful response rates of 72.7% ACR20, 54.5% ACR50 and 35.8% ACR70 at Week 16 in the open label period of its trial in difficult-to-treat rheumatoid arthritis (D2T RA)... ► Artikel lesen | |
| MINERALYS THERAPEUTICS | 15,990 | 0,00 % | Mineralys Therapeutics, Inc. - 8-K, Current Report | ||
| ERASCA | 14,660 | 0,00 % | Erasca, Inc.: Erasca Reports Second Quarter 2026 Business Updates and Financial Results | Updated ERAS-0015 data in U.S. trial highlighted compelling monotherapy efficacy in 2L+ KRAS G12X PDAC and continued favorable tolerability, as well as further advancement of panitumumab CRC combination... ► Artikel lesen | |
| ADMA BIOLOGICS | 11,120 | +0,09 % | ADMA Biologics, Inc.: ADMA Biologics to Report Third Quarter 2026 Financial Results on November 4, 2026 | ||
| ZENAS BIOPHARMA | 28,380 | 0,00 % | Zenas BioPharma Announces Submission of Biologics License Application (BLA) to U.S. FDA for Obexelimab in IgG4-RD | - BLA submission based on positive results from Phase 3 INDIGO trial - WALTHAM, Mass., May 28, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. ("Zenas," "Zenas BioPharma" or the "Company") (Nasdaq:... ► Artikel lesen | |
| ALAMAR BIOSCIENCES | 30,220 | 0,00 % | Alamar Biosciences, Inc.: Alamar Biosciences Partners with GSK on Large-Scale Proteomic Study to Advance Precision Medicine | Alamar's NULISAseq Immune 340 and NULISAseq Neuro 220 panels will be used to investigate disease progression, biological subtypes and treatment responseFREMONT, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 37,710 | +0,08 % | Edgewise Therapeutics Doses First Patient in Phase 2 EQUINOX-HFpEF Trial of EDG-15400 | - Phase 2 trial evaluating EDG-15400 in adults with symptomatic HFpEF with a LVEF of at least 50% -
- EQUINOX-HFpEF trial design and EDG-15400 Phase 1 first-in-human... ► Artikel lesen | |
| DYNE THERAPEUTICS | 18,060 | +0,06 % | Shandong Wit Dyne Health Co., Ltd. Profit Drops In Nine Months | ||
| TREVI THERAPEUTICS | 13,860 | 0,00 % | Trevi Therapeutics: Wie ein Nischenmedikament zum strategischen Hebel für den Milliardenmarkt Reizhusten werden könnte | Trevi Therapeutics steht kurz davor, mit Haduvio ein erstes Nischenprodukt in den US-Markt zu bringen und damit einen "specialty beachhead" zu etablieren, der als Plattform für eine mögliche Expansion... ► Artikel lesen | |
| COGENT BIOSCIENCES | 31,080 | +0,06 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces FDA Acceptance of New Drug Application (NDA) for Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) | NDA supported by positive results from the APEX pivotal trial demonstrating clinically meaningful responses and evidence of disease modification in patients with AdvSM PDUFA target action date set... ► Artikel lesen | |
| VOR BIOPHARMA | 19,860 | 0,00 % | Stifel reiterates Vor Biopharma stock rating on trial milestone |
CARSGEN THERAPEUTICS HOLDINGS LTD gehört der Branche Biotechnologie an.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CARSGEN THERAPEUTICS HOLDINGS LTD finden Sie auf Wallstreet Online.